9 results
The primary objective of the clinical part of EPISTOP project is to identify the clinical and molecular biomarkers of epileptogenesis in a prospective clinical study of patients with TSC. Secondary objective of the clinical part of EPISTOP is to…
Aim: This research will look at the implicit and explicit drug-related cognitions, at the effect of marketing cues on brain activity, and at the effect on aggressive behaviour, in alcohol users, cannabis users, and a control group. These effects…
In this study we will investigate whether there is cross tolerance for the effects of alcohol and cannabis. Therefore we will investigate both the pharmacodynamic and pharmacokinetic effects of a combined administration of cannabis and alcohol.
Primary Objective: to assess the immediate and delayed effects of THC on true and false memories in a legal context (i.e., on eyewitness and offender statements).Secondary Objective(s): to link drug-induced false memory effects to dissociation
Primary Objective- To investigate the ability of TMS-EEG measures to detect effects on cortical excitability of valproic acid, levetiracetam and lorazepam in healthy subjects- To investigate the ability of TMS-EMG measures to detect effects on…
- To evaluate effects of levetiracetam 2000 mg on single and paired pulse TMS-EMG and TMS-EEG in patients with epilepsy treated with mono-therapy levetiracetam, when compared to placebo (levetiracetam trough concentrations). - To evaluatethe effects…
To compare invasive disease-free survival (iDFS) for ribociclib + ET versus placebo + ET in patients with HR-positive, HER2-negative, EBCwith high risk of recurrence.
In this study, we want to know more about the acute effects of cannabis on neurotransmitter systems. For this, we compare the effects of cannabis with the effects of placebo in 50 healthy participants, both occasional and chronic users. During and…
Primary: To compare PFS between ribociclib plus fulvestrant to fulvestrant monotherapy (plus placebo) among men and postmenopausal women with HR+, HER2-negative advanced breast cancer who received no or only one prior endocrine treatment for…